Sunday, January 26, 2025
HomeIndustries

Industries

BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults

BioMarin Pharmaceutical Inc. announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety...

Truwl Releases Free Benchmarking Tool for Genomics

Truwl , a Montana-based bioinformatics company, announced that it is releasing a free version of its germline variant-calling benchmarking workflow to remove cost as...

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

Ascletis Pharma Inc.  announces the approval of the Investigational New Drug (IND) application by U.S. Food and Drug Administration (FDA) for in-house developed oral...

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced...

Everest Medicines Announces First Drug Approval of Trodelvy in Singapore

Everest Medicines , a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced...
0FansLike
0FollowersFollow
spot_img

Hot Topics